Advancis Pulsatile Amoxicillin NDA Planned For 2005; Par Marketing To Focus On Pediatrics
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III program in adults and children will test a once-daily, five-day regimen of oral amoxicillin PULSYS totaling 5 g of antibiotic vs. 10 days of twice-daily conventional amoxicillin totaling 17.5 g of drug.
You may also be interested in...
Par Planning Megace ES Launch In Summer 2005 With In-House Sales Force
Par is looking for a second product to detail with the 50-60 person force it is building for extra strength Megace. The company hopes to get an "approvable" letter for the product in April and begin detailing in July.
Par Planning Megace ES Launch In Summer 2005 With In-House Sales Force
Par is looking for a second product to detail with the 50-60 person force it is building for extra strength Megace. The company hopes to get an "approvable" letter for the product in April and begin detailing in July.
Lilly Sells Keflex Antibiotic To Advancis; Plans For Once-Daily Dosing Underway
Advancis will commence clinical trials with Keflex using proprietary Pulsys drug delivery technology. The company also has Pulsys agreements with GSK for Augmentin and with Par for amoxicillin.